Thirty-one patients with nonhemorrhagic shock or hypotension of diverse etiologies accompanied by low cardiac output and normal or low right atrial pressure were given a rapid infusion of dextran. Cardiac output returned to normal in 20 patients and shock or hypotension was corrected in 16.
SUMMARY
Thirty-one patients with nonhemorrhagic shock or hypotension of diverse etiologies accompanied by low cardiac output and normal or low right atrial pressure were given a rapid infusion of dextran. Cardiac output returned to normal in 20 patients and shock or hypotension was corrected in 16. In 10 patients with evidence of vasoconstriction and normal cardiac function, dextran reversed the circulatory abnormality, returning blood pressure, cardiac output, and peripheral vascular resistance to normal. Twelve patients with hypotension without evidence of reflex vasoconstriction were improved by dextran but the hypotension persisted occasionally. In nine patients, dextran revealed heart failure as manifested by a precipitous rise in right atrial pressure without much increase in cardiac output. Control hemodynamic observations and the response to dextran could not necessarily be predicted from the nature of the disease which precipitated the shock.
The efficacy of a rapid infusion of low molecular weight or clinical dextran associated with its freedom from significant toxicity should make it the treatment of choice in nonhemorrhagic shock of any cause associated with normal central venous pressure.
ADDITIONAL INDEXING WORDS:
Cardiac output Peripheral vascular resistance DEXTRAN is a polysaccharide which has been widely used as a plasma volume expander in the treatment of shock associated with blood or plasma loss.' Recent observations indicate that lower molecular weight dextran also has a direct rheological effect in inhibiting red cell sludging and improving blood flow.2 All dextran preparations consist of mixtures of molecules of varying size, but the average molecular weight of the clinical dextran used in this country is 75,000, while that of the newer low molecular weight preparation, dextran 40 (Rheomacrodex), introduced in Sweden is 40,000. This study was supported in part by U.S. Public Health Service Research Grant HE-0978501 from the National Heart Institute and a grant-in-aid from the Washington Heart Association. 316 Central venous pressure The observation that medical shock not precipitated by obvious blood volume loss is often accompanied by a low or normal central venous pressure3 suggested that volume expansion in these situations might be beneficial. A preliminary study4 indicated that rapid infusion of either dextran 75 or dextran 40 was far more effective than the vasopressor drugs in restoring a normal cardiac output in patients with nonhemorrhagic shock or hypotension.
The purpose of the present study is to analyze in detail the hemodynamic response to the rapid infusion of dextran in 31 patients with nonhemorrhagic shock or hypotension and in eight normal volunteers.
Methods
All patients were males hospitalized in the Veterans Administration Hospital. They were selected for study because of severe hypotension occurring during the course of a serious medical illness or because the diagnosis of clinical shock Circulation, Volume XXXV, February 1967 CLINICAL SHOCK AND HYPOTENSION was made on the basis of low auscultatory blood pressure associated with cool, moist skin, oliguria, and disturbance in mentation. Intra-arterial pressure was not reduced in some of the latter patients.5 None of the patients had evidence of significant blood or plasma loss. Studies were performed at the bedside6 as soon as possible after the diagnosis of hypotension or shock. Many patients were studied soon after the onset of the circulatory disturbance and before any specific therapy to support blood pressure had been instituted. In some instances, however, vasopressor drugs had been employed for variable periods prior to the hemodynamic measurements.
The volunteer subjects were male patients hospitalized for illnesses unrelated to the cardiovascular system. They were studied in a catheterization laboratory in the morning after an overnight fast.
All patients were studied in the supine position. A catheter was threaded into the right atrium through a needle in the femoral vein. The femoral artery was cannulated either with a Cournand needle or with a polyethylene catheter inserted by the Seldinger technique. Pressures were measured with a Statham P23Db strain gauge transducer, carrier preamplifier, and Sanborn recorder. Mean pressures were obtained by electrical integration. Cardiac output was measured by the indicator-dilution method. Indocyanine green was injected into the right atrium while femoral arterial or aortic blood was drawn through a Gilford cuvette densitometer, using a Gilford constant withdrawal pump.
Cardiac output, peripheral vascular resistance, central blood volume, and left ventricular stroke work were calculated by methods previously described. 7 Blood volume was measured with T 1824. The disappearance slope for T 1824, determined by multiple arterial sampling, was extrapolated logarithmically to the time of injection for determination of plasma volume. The effect of dextran on plasma volume was determined by collecting blood samples at intervals before and after dextran infusion. The difference between T 1824 concentrations after dextran and the predicted T 1824 concentration was determined from the disappearance slope before dextran was used to calculate the expansion of plasma volume which occurred. Blood volume was calculated from the plasma volume by means of the arterial hematocrit which was corrected for plasma trapping8 and multiplied by 0.91 to correct for the discrepancy between large vessel and total body hematocrit. 9 Control observations were carried out during a period when blood pressure was stable and no vasoactive diugs were being administered. If a Circulation, Volume XXXV, February 1967 vasopressor drug had been infused, this was discontinued, and arterial pressure was allowed to fall until it stabilized before hemodynamic studies were performed. Patients were selected foi dextran infusion if cardiac output was reduced and mean right atrial pressure was less than 8 mm Hg. Twenty-five of the patients and seven of the volunteers received infusions of 10% dextran 40 (Rheomacrodex) in either 5% dextrose or normal saline. Six patients and the other volunteer received 6% dextran 75 (Macrodex) in saline. All infusions were administered under pressure and were completed within 10 to 20 minutes, when hemodynamic studies were repeated. All but two subjects received 500 ml dextran. Patient H.B. was given 1,000 ml dextran 75, and in patient W.H. the infusion of dextran 40 was stopped after 250 ml had been administered because of a precipitous rise in right atrial pressure.
Statistical analyses were performed with the Student's t-test.'0
Results
Hemodynamic effects of the infusion of dextran in the patients with shock and hypotension are shown in table 1. The effects in the normal subjects are shown in table 2.
Cardiac Output and Peripheral Vascular

Resistance
Cardiac output (CO) was below the normal range in the control period in each of the patients, averaging 2,937 ml per min. Infusion of dextran increased the output in all but one patient, the mean rising to 4,842 ml per min. No significant difference was noted in the output response to the two dextran preparations. Dextran 75 increased CO by an average of 1,851 ml per min in six subjects and dextran 40 increased it by 1,919 ml per min in 25 subjects.
Peripheral vascular resistance (PVR) in the control period was greater than 1,500 dynesec-cm-5 in ten patients without evidence of heart failure. These patients usually had cool, moist skin and thready peripheral pulses and were classified as 'vasoconstricted.""1 Twelve patients without heart failure had calculated PVR less than 1,500 dyne-sec-cm-5 They usually had warm skin and full pulses and were classified as "nonvasoconstricted." 
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CDO 000 000 CO 000 00 0 000 N 0 cO co 00 cO 10 CO CO 0 000 c 0 0 0 the nonvasoconstricted group (P < 0.01) ( fig.  1 ). PVR in the former group fell from an average of 2,227 to 1,215 dyne-sec-cm-5 and was reduced to less than 1,500 dyne-sec-cm-5 in all patients except L.C. and I.M. Further dextran administration subsequently restored the output and PVR in patient I.M. to normal. RIGHT ATRIAL PRESSURE (mm HgI Figure 1 Mean response to infusion of dextran in patients with shock or hypotension and in normal subjects. Cardiac function curve shifted to left in vasoconstricted patients and to right in those with heart failutre.
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n the 12 nonvasoconstricted subjects, PVR fell from 1,236 to 971 dyne-sec-cm-5.
In nine patients an inadequate CO response to dextran associated with a precipitous rise in right atrial pressure (RAP) was accepted as evidence of "heart failure." Three of these subjects had acute myocardial infarctions, one had cor pulmonale, and one had arteriosclerotic heart disease with a superimposed infection. The other four, however, had no known heart disease but were suffering from severe, febrile, infectious disease. In these nine patients CO increased an average of 1,125 ml per min ( fig. 1 ), while PVR fell from 2,042 to 1,290 dyne-sec-cm-5. Output decreased in one patient (C.S.) after dextran infusion.
In eight normal subjects CO increased from an average of 5,506 to 7,543 ml per min (fig.  1 ), and PVR decreased from 1,467 to 1,125 dyne-sec-cm-5. Output rose in seven subjects and was essentially unchanged in one.
Arterial Pressure
Mean arterial pressure rose after dextran from an average of 60.9 to 73.2 mm Hg, and pulse pressure increased from 38 to 54 mm Hg. Femoral arterial pressure in the vasoconstricted patients rose from an average Effect of dextran infusion on arterial pressure and heart rate. Cardiac slowing occurred in all three groups of patients with shock but not in the normal subjects.
of 108/63 to 140/71 mm Hg (fig. 2 ). Two patients (A.J. and F.P.) with clinical signs of shock but normal or high arterial pressure exhibited a slight fall in blood pressure after dextran.
In the nonvasoconstricted patients arterial pressure was increased from 78/42 to 103/52 mm Hg (fig. 2 ). In six patients, however, systolic pressure remained below 100 mm Hg immediately after infusion of dextran.
In the patients with heart failure, arterial pressure rose from an average of 83/50 to 91/53 mm Hg (fig. 2) . Two patients exhibited a slight fall in arterial pressure after dextran. One of them (H.M.) had a high arterial pressure during the control period.
Arterial pressure was changed little in normal subjects, rising from an average of 130/80 to 138/83 mm Hg (fig. 2 ).
Heart Rate, Stroke Volume, and Stroke Work
Heart rate slowed in all groups of patients from an average of 103 to 95 beats per minute (P<0.01) ( fig. 2 ). The combination of increased CO and cardiac slowing produced a striking increase in stroke volume from an average of 31 to 56 ml per beat.
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Left ventricular end-diastolic pressure was not measured, but since the rise in left atrial pressure with volume expansion should be directly proportional to the rise in RAP,'2 the RAP was subtracted from mean arterial pressure in the calculation of left ventricular stroke work. Stroke work increased from an average of 25 to 52 g-m. The response was most pronounced in the vasoconstricted subjects who exhibited an increase from an average of 25 to 68 g-m. In the nonvasoconstricted patients it nearly doubled from 30 to 57 g-m, while stroke work in those with heart failure increased only from 19 to 29 g-m.
In the normal subjects, dextran infusion did not alter heart rate but increased stroke volume from an average of 76 to 105 ml and stroke work from 98 to 141 g-m.
Right Atrial Pressure and Central Blood Volume
Mean RAP increased in all the subjects, rising from an average of 0.1 to 4.6 mm Hg ( fig. 1 ).
Central blood volume (CBV) increased an average of 319 ml in the 28 subjects who received 500-ml infusions. There was no difference in the response to dextran 40 and 321 COHN ET AL. Mean effect of 500-ml infusion of dex blood volume in the three groups o) shock or hypotension. dextran 75. CBV increased by a 447 ml in vasoconstricted patients 264 ml in nonvasoconstricted su ever, the difference did not rea significance (0.05 < P < 0.1). P heart failure had a larger CBV i period and exhibited an increa 318 ml after 500 ml of dextran (f Total Blood Volume Total blood volume was mea control period in 29 of the patiei none had sustained significant e: 8L00D VOLUME lmtlkgl Figure 4 Relationship between initial total blo cardiac output response to dextran with shock or hypotension. Significant diac output was not limited to patient blood volume.
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Lch statist of blood, blood volume was moderately reduced in many subjects, averaging 59 ml/kg compared with a normal value of 69 ml/kg.7 Blood volume was lowest in the vasoconstricted patients," averaging 55 ml/kg in this group and 63 ml/kg in the nonvasoconstricted patients.
While reduced blood volume may have been of some importance in the magnitude of the CO response to dextran ( fig. 4 ), the finldings in individual patients varied widely. Hypovolemia was not a prerequisite for a significant increase in CO after dextran infusion either in patients with shock or in the normal subjects ntral ( increased, and the patients became more alert.
The hypotension or shock was corrected by dextran alone in 16 of the 31 patients, ten requiring only the initial 500-ml infusion while six others required additional dextran because of persistent or recurrent signs of low CO with normal central venous pressure. Although some of these patients later died of their underlying disease, circulatory failure was not an obviously contributing factor. Shock was also corrected in three other patients who required digitalis or vasopressor drugs in addition to dextran. Eight of the ten vasoconstricted patients and nine of the CLINICAL SHOCK AND HYPOTENSION function. No bleeding phenomena which could be related to the dextran were observed, and no patients exhibited acute allergic reactions. One patient who received 4 L of dextran over a ten-day period developed unexplained eosinophilia two weeks later. Urine output usually increased following dextran, and no episodes of renal shutdown attributable to the dextran were observed.
Discussion
The patients in this series had a diversity of medical diseases associated with severe hypotension or clinical shock. The low cardiac output, which was a constant finding, supports the generally accepted concept that the principal circulatory abnormality in shock is a deficiency of blood flow. '3-16 The effectiveness of dextran in augmenting cardiac output must be attributed to an increased venous return to the heart since the polysaccharide has no direct cardiac effect and the rise in output was always associated with an increase in right atrial pressure. The simplest interpretation would be that these patients suffered from volume depletion and that dextran, by increasing blood volume a little more than 500 ml, restored normal hemodynamics. However, several observations cast doubt on this as the sole explanation for the response: (1) None of the patients sustained external losses of blood volume, and although moderate hypovolemia was present in many, intravascular volume was rarely reduced by the 30% usually encountered in hemorrhagic and traumatic shock ( fig. 4 ). 17 (2) Dextran disappears from the circulation, the smaller molecules more rapidly than the larger ones,18 but many of the patients experienced permanent correction of their hemodynamic abnormality with a single 500-ml infusion. (3) Volume expansion with blood or saline in amounts far in excess of 500 ml does not predictably increase cardiac output in normal subjects,'9 20 while dextran in this and previous studies21 produced a rise averaging about 35%.
The rheological properties of dextran may be important in the hemodynamic response.
Dextran reduces the viscosity of whole blood
Circulation, Volume XXXV, February 1967 at all shear rates,22 and the lower molecular weight particles inhibit red cell aggregation.2 23, 24 Since red call sludging and microthrombi may occur in a variety of shock states,25-27 dextran, by reversing these phenomena, could speed capillary flow, further reduce blood viscosity,28 and perhaps also mobilize sequestered red cells. 29 The result would be a decrease in resistance to flow and an increase in vis a tergo and in venous return to the heart.30 This result, combined with the volume expansion from the dextran, would produce a profound increase in cardiac output. Dextran, therefore, may have the unique property of augmenting venous return by several mechanisms without having a direct vascular effect. Anemia resulting from infusion of dextran would further reduce blood viscosity, but it is unlikely that the change in oxygen-carrying capacity from a hematocrit fall averaging only 8 vol% was an important factor in the hemodynamic response.
Whereas patients with a low cardiac output and an elevated cardiac filling pressure may be assumed to be suffering, at least in part, from failure of the heart, the adequacy of cardiac function is not necessarily known in patients with low cardiac output and normal or low atrial pressure. At the time of observation these latter patients may be operating on the lower end of either a normal or an abnormal function curve.3' Measurement of the change in cardiac output as ventricular filling is acutely augmented is the most practical way to assess the pumping ability of the heart. 32 The response to rapid infusion of dextran in these patients could not necessarily be predicted from their underlying medical disease. Twenty-two of the 31 patients exhibited adequate cardiac function, including six of nine patients with acute myocardial infarctions and several elderly patients with arteriosclerotic heart disease and previous episodes of congestive heart failure. Others with no history of heart disease and shock not obviously precipitated by a cardiac cause demonstrated severe myocardial impairment at the time of study. Although left ventricular filling pressure was not measured in these patients, it is likely that right atrial pressure would rise with left atrial pressure during volume expansion. 12 In no instance did dextran infusion lead to signs or symptoms of pulmonary congestion.
On the basis of control hemodynamics, these patients could be separated into "vasoconstricted" and "nonvasoconstricted" groups. The vasoconstricted patients had high total peripheral vascular resistance, higher central blood volumes, and more rapid heart rates and were usually hypovolemic. The nonvasoconstricted patients had low or normal PVR, lower CBV, and slower heart rates and were usually normovolemic.11 The hemodynamic pattern again could not be predicted from the disease state, although there was a high incidence of alcoholism, cirrhosis, malignancy, and emphysema in the nonvasoconstricted patients."1
The rise in cardiac output after dextran in the nonvasoconstricted patients followed a normal function curve practically identical to the slope of the mean response in normal subjects ( fig. 1 ). In the vasoconstricted patients the output increased significantly more, and the mean cardiac function curve was shifted to the left of that observed in the normal and nonvasoconstricted patients. This shift of the function curve is typical of the effect on the heart of catecholamines3' and suggests that these patients were undergoing adrenergic cardiac stimulation at the time of observation. Cardiac slowing occurred in all patients given dextran but was most marked in the vasoconstricted group, who had more rapid rates in the control period. The slightly greater rise in central blood volume after dextran in the vasoconstricted as against the nonvasoconstricted patients ( fig. 3 ) suggests that diminished venous compliance from adrenergic stimulation may have limited peripheral distribution of the augmented blood volume.
The deleterious circulatory effects of prolonged vasoconstriction have been stressed by Nickerson.33 Not only may it lead to tissue hypoxia, but it results in intravascular pooling or loss of plasma volume, which aggravates the flow deficiency. The patients in this series with high calculated total peripheral vascular resistance appeared clinically to have skin vasoconstriction and were probably under the influence of heightened sympathetic nervous system activity.34 Numerous pharmacological agents have been recommended to combat this reflex vasoconstriction, including adrenergic blocking agents, ganglionic blocking agents, vasodilators, isoproterenol, and corticosteroids. Dextran reduced the peripheral vascular resistance in all patients in this series, restoring it to the normal range in most vasoconstricted patients, while the clinical signs of vasoconstriction usually disappeared as well. Some of the effect on resistance could be explained by the direct rheological properties of dextran and by the passive effect of an increased transmural pressure. However, most of the decrease in peripheral vascular resistance was probably related to the increased cardiac output and subsequent relaxation of reflex sympathetic discharge.
The rapidity with which dextran was administered may have been of importance in the response. Rapid infusion not only would help to produce rheologically effective dextran blood levels,24 but an acute increase in venous return and cardiac output might be vital in the relaxation of reflex vasoconstriction. In the vasoconstricted patient, dextran administered by slow infusion might not significantly increase plasma volume because of continued pooling or loss from the intravascular space.
The restoration of normal hemodynamics after dextran in the vasoconstricted patients suggests that their principal circulatory abnormality was a deficient venous return due to loss of circulating intravascular volume. Although reduced venous return and cardiac output were also manifestations of the nonvasoconstricted patients, it is unlikely that this was their sole hemodynamic abnormality. The absence of reflex vasoconstriction in response to low blood pressure35 and the fact that many of these patients remained hypotensive after the output had been restored to a normal level with dextran indicate that these patients Circulation, Volume XXXV, February 1967 324 CLINICAL SHOCK AND HYPOTENSION had a disturbance in peripheral vascular regulation. In the patients whose right atrial pressure rose to abnormal levels, the persistence of hypotension or shock was clearly due to inability of the heart to pump an adequate volume of blood. Since central venous pressure was normal in the control period in each of these patients, the importance of the dextran infusion was the unmasking of functional impairment of the heart. Other factors may have been involved in the onset of the low cardiac output in these patients, but significant improvement in the circulatory abnormality would be impossible unless cardiac function were improved.
The demonstration of adequate cardiac reserve in most of these critically ill patients with severe hypotension and shock is strong evidence that cardiac deterioration need not be a factor in shock. Some of the patients with impaired cardiac function may have been in a more advanced shock state, which can be associated with heart failure.36 Since seven of these patients died despite treatment, it is apparent that cardiac impairment adversely affects the prognosis in shock. While these patients clearly require an inotropic agent, routine use of digitalis or other cardiac stimulating drugs in all patients with shock or hypotension appears unnecessary.
The efficacy and safety of dextran commend it as the treatment of choice in all types of hypotension and shock associated with a low or normal central venous pressure. The low molecular weight preparation has several theoretical advantages over clinical dextran in the treatment of nonhemorrhagic shock. Its higher concentration (10%) results in greater acute volume expansion by the mobilization of extravascular fluid, and its more rapid disappearance from the circulation minimizes the dangers of overexpansion. The lower molecular weight particles also have greater rheological properties and produce coagulation defects less often.37 However, in this limited series the hemodynamic response to dextran 75 was similar to that after dextran 40.
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